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This study was conducted to determine whether the integration of the Hematopoietic Cell Transplantation
Comorbidity Index (HCT-CI) and the European Group for Blood and Marrow Transplantation (EBMT) score
would improve individual capacity for stratiﬁcation of high-risk HCT candidates. A total of 442 consecutive
patients receiving an allogeneic HCT after reduced-toxicity conditioning was included. Final HCT-CI and EBMT
scores were calculated and validated. Then, patients were grouped into a 6-category new combination model
according to the HCT-CI (0, 1 to 2, 3) and EBMT scores (0 to 3, 4 to 7), and the model’s predictive capacity
was also evaluated. Median HCT-CI and EBMT scores were 3 and 4, respectively. Increased HCT-CI was
associated with higher 4-year nonrelapse mortality (NRM) and lower 4-year overall survival (OS), whereas a
high EBMT score was associated with higher 4-year NRM. The HCT-CI showed a trend for a better predictive
capacity than the EBMT score (c-statistic .6 versus .54, P ¼ .1). According to the new model, patients within
HCT-CI of 0 and HCT-CI of 1 to 2 groups had similar risk of NRM independently of their EBMT score. Within
the HCT-CI  3 group, patients with low EBMT score showed lower NRM (25% versus 40%, P ¼ .04) and a trend
to higher OS (52% versus 36%, P ¼ .06) than patients with a high EBMT score. Moreover, patients with HCT-CI
 3 and EBMT score 0 to 3 had similar outcomes than those with HCT-CI of 1 to 2. In conclusion, the com-
bination of HCT-CI and the EBMT score is feasible and might contribute to a better identiﬁcation of high-risk
patients, improving selection of best allogeneic HCT candidates.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT)
is inherently associated with a risk of nonrelapse mortality
(NRM) that varies greatly depending on transplant and pa-
tient characteristics. The assessment of the risk of compli-
cations and mortality before the procedure is extremely
important when facing the decision of transplant indication,
conditioning regimen, and patient counseling.
With the advent of reduced-toxicity conditionings
(including reduced-intensity and nonmyeloablative condi-
tionings), the indication of allo-HCT has been expanded. In
this setting, a careful assessment of the risk of complications
after the procedure is of utmost importance because
reduced-toxicity conditioned allo-HCT recipients are older
and have more and severer comorbidities than patients
receiving conventional myeloablative allo-HCT [1].edgments on page 71.
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13.10.011Several pretransplant models [2-5] have been developed
to predict the outcome after allo-HCT through the selection
of the best candidates and conditioning regimens. Two
models have emerged as the most popular, 1 on each side of
the Atlantic: the HCT Comorbidity Index (HCT-CI) and the
European Group for Blood and Marrow Transplantation
(EBMT) score. The former summarizes 17 comorbid condi-
tions of the patients before transplantation, whereas the
latter is a global prognostic model including several
transplant-related variables. These models have been vali-
dated by several groups in several transplant and diseases
settings [6-10]. However, their predictive capacity for a
particular patient is limited, suggesting that further
improvement is still needed in this setting.
Considering that these 2 models are focused on different
pre-HCT characteristics (HCT-CI on comorbidities and the
EBMT score on more classical risk factors), we hypothesized
that the combination of the 2 could improve their individual
predictive capacity. To thatend,weconducteda study ina large
and homogeneous population of patients receiving reduced-
toxicity allo-HCT. Each model was individually evaluated, and
thena full integrationof bothmodelswas conducted toexplore
the possible role in the identiﬁcation of high-risk patients.Transplantation.
Table 1
Patient Characteristics (N ¼ 442)
Characteristic Value
Median age, yr (range) 53 (16-71)
Gender, male, n (%) 268 (61)
Female donor to male recipient 115 (26)
Underlying disease, n (%)
Acute leukemia and MDS 156 (35)
Hodgkin lymphoma 56 (13)
NHL and CLL 125 (28)
Multiple myeloma 72 (16)
Others 33 (7)
Advanced disease status at HCT,* n (%) 209 (47)
Recipientedonor CMV serology, n (%)
Recipient and donor negative 49 (11)
Other 393 (89)
Donor type, n (%)
HLA identical sibling 353 (80)
Alternative (VUD or MsM related) 89 (20)
Conditioning regimen, n (%)
Fludarabine-melphalan 270 (61)
Fludarabine-busulfan 146 (33)
Other 26 (6)
Peripheral blood stem cells, n (%) 422 (95)
Alemtuzumab or ATG-based conditioning, n (%) 60 (14)
GVHD prophylaxis, n (%)
CsA-MTX 288 (65)
CsA-MMF 128 (29)
Other 26 (6)
Year of HCT, median (range) 2003 (1999-2008)
Median follow-up for survivors, mo (range) 53 (3-123)
MDS indicates myelodysplastic syndrome; NHL, non-Hodgkin lymphoma;
CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; VUD, volunteer
unrelated donor; MsM, HLA mismatch; ATG, antithymocyte globulin; CsA,
cyclosporine A; MTX, methotrexate; MMF, micophenolate mophetil.
* Advanced disease status: acute leukemia in >2nd complete remission,
chronic myeloid leukemia in blastic phase, Hodgkin disease, lymphomas
and multiple myeloma in 3rd remission. Other patients with partial
remission or persistent disease at transplantation (except for myeloma and
Hodgkin disease) were also considered as advanced disease.
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The study included all consecutive adult patients who received an allo-
HCT with reduced-toxicity conditioning in the Hospital Vall d’Hebrón
(Barcelona), Hospital de Sant Pau (Barcelona), Hospital Universitario (Sala-
manca), and Hospital Clínic (Barcelona) between February 1998 and
November 2008. The transplant protocol was approved by local and national
ethics committees, and patients gave written informed consent for their
inclusion in the protocol.
Transplant Procedure
The transplant protocol was published elsewhere in detail [11]. In brief,
conditioning regimen for all patients included ﬂudarabine (150 mg/m2) in
combinationwith melphalan (70 to 140mg/m2; lymphoidmalignancies and
multiple myeloma), busulfan (8 to 10 mg/kg; myeloid malignancies, except
for chronic myeloid leukemia), cyclophosphamide (120 mg/kg; solid ma-
lignancies), or low-dose total body irradiation (2 Gy; chronic myeloid leu-
kemia). Although the above combinations may not be strictly considered as
reduced-intensity conditioning regimens (ie, ﬂudarabine and busulfan
10 mg/kg) [12], the aim of this protocol was to expand transplant indication
to older and unﬁt patients. Thus, in line with other investigators [13], these
regimens are referred to as reduced-toxicity conditionings throughout the
article.
Reduced-toxicity conditioning was preferred over myeloablative con-
ditioning in patients 50 years of age and with previous HCT and severe
comorbidities. Graft-versus-host disease (GVHD) prophylaxis included a
calcineurin inhibitor (mainly cyclosporine A) and short-course metho-
trexate (day þ1 at 15 mg/m2 and days þ3,þ6, þ11 at 10 mg/m2, with folinic
acid rescue) or cyclosporine A plus mycophenolate mofetil. In vivo T cell
depletion was used in patients receiving a transplant from HLA mismatched
related or unrelated donors (antithymocyte globulin or alemtuzumab).
Advanced risk for baseline disease was deﬁned following the EBMT criteria
[3] and is summarized in Table 1.
Acyclovir, ﬂuconazole, and quinolones were administered as infectious
prophylaxis. Cytomegalovirus infection screening (using antigenemia pp65
before 2003 and RT-PCR after that year) for guiding preemptive therapy
and Galactomannan Platelia assay (Bio-Rad Laboratories, Hercules, CA, since
2003) determinations in blood and serum samples were performed as
described [14,15].
Regarding HLA typing, family donors were tested for HLA-A, -B (low
resolution), and -DRB1 (high resolution). Unrelated donors were tested for
HLA-A, -B, -C, -DRB1, and -DQB1 (high resolution).
Predictive Models
The HCT-CI and the EBMT score were calculated as originally deﬁned
[2,3]. All patients underwent laboratory studies, pulmonary function tests,
and echocardiography performed in each center within day 30 and
day 10 of HCT.
Calculation of the HCT-CI and EBMT scores was retrospectively per-
formed based on medical records and results of pretransplant studies. Ac-
cording to the HCT-CI, patients were grouped by low risk (HCT-CI ¼ 0),
intermediate risk (HCT-CI¼ 1 to 2), or high risk (HCT-CI 3) per Sorror et al.
[2]. Regarding the EBMT score, patients were classiﬁed as 0 to 2, 3, 4, 5, or 6
to 7 to ensure at least 5% of patients in each group.
The individual predictive capacity of the HCT-CI and the EBMT score for
NRM and overall survival (OS) was evaluated. Thereafter, a new combination
model was built based on the risk group of bothmodels. To limit the number
of categories of the new model, the EBMT score was categorized into high-
and low-risk groups according to themedian score (low risk for EBMT scores
from 0 to 3 and high risk for EBMT scores from 4 to 7). The ﬁnal 6-category
combination model classiﬁed patients as follows: group 1, HCT-CI ¼ 0 and
EBMT score ¼ 0 to 3; group 2, HCT-CI ¼ 0 and EBMT score ¼ 4 to 7; group 3,
HCT-CI¼ 1 to 2 and EBMT score¼ 0 to 3; group 4, HCT-CI¼ 1 to 2 and EBMT
score ¼ 4 to 7; group 5, HCT-CI  3 and EBMT score ¼ 0 to 3; and group 6,
HCT-CI  3 and EBMT score 4 to 7.
Endpoints, Deﬁnitions, and Statistical Analysis
The primary endpoint of the study was NRM deﬁned as the time from
day 0 of the transplant to death from any cause but relapse/progressive
disease. Secondary outcomes were OS deﬁned as the time from day 0 of the
transplant to death from any cause and description of the patient distribu-
tion according to both models.
Neutrophil and platelet engraftment were deﬁned as the ﬁrst of 3
consecutive days with neutrophil count >.5  109/L (without granulocyte
colony-stimulating factor support) and transfusion-independent platelet
count >50  109/L, respectively. Patients dying before day þ100 were not
considered for chronic GVHD analysis.
The incidence of NRM, GVHD, and relapse were calculated using cu-
mulative incidence estimates, taking into account the competing risk model,considering relapse as a competitive event [16]. The probability of OS was
estimated using Kaplan-Meier curves and compared using log rank tests
[17]. Univariate Cox regression analysis was used to estimate risk factors of
4-year NRM and OS. The possible risk factors for early (100-day) NRM were
analyzed by using logistic regression. Variables tested in the univariate Cox
regression analysis for transplant outcomes are listed in Table 2. Multivariate
analysis (MVA) was performed taking into account the competing risk
structure. The HCT-CI and the EBMT score were forced into the MVA model.
Other pretransplant variables were included in the MVA model when a
signiﬁcance level of P  .1 was detected in the univariate Cox regression
analysis. A signiﬁcance level of P  .05 (2 sided) was required in the MVA. In
the risk factor analysis of the EBMT score, variables already included in the
score were not included in the MVA. The c-statistic was calculated to esti-
mate the predictive capacity of the HCT-CI and EBMT score for NRM, as
previously described [18]. All statistical analyses were performed using SPSS
version 17.0 (SPSS, Chicago, IL) and NCSS 2004 (Number Cruncher Statistical
System, Kaysville, UT).
RESULTS
Patient Characteristics
Of the 468 transplanted patients, 442 had enough data for
HCT-CI and EBMT score calculation and were included in the
study. Pretransplant characteristics of the patients in the
study are listed in Table 1. In brief, median age at trans-
plantation was 53 years (range, 16 to 71). Most patients
received allo-HCT from HLA identical sibling donors
(n ¼ 353, 80%) mainly for acute leukemia and myelodys-
plastic syndromes (n ¼ 156, 35%). Median follow-up for
survivors was 53 months (range, 3 to 123).
HCT-CI and EBMT Score
The median HCT-CI and EBMT scores were 3 (range, 0 to
13) and 4 (range, 1 to 7), respectively. Patient distribution
Table 2
Univariate and Multivariate Analysis of Pretransplant Variables on Transplant Outcomes
Variables 100-Day NRM P 4-Year NRM P 4-Year OS P
Univariate analysis
Male vs. female 1.2 (.7-2.1) .5 1 (.7-1.5) .7 1.1 (.9-1.5) .4
Age > 60 .9 (.5-1.8) .8 1.7 (1.2-2.5) .007 1.5 (1.1-2) .01
HLA alternative 2 (1.1-3.8) .02 1.7 (1.2-2.5) .006 1.3 (1.1-1.9) .03
Female to male .8 (.4-1.5) .5 1.5 (1-2.1) .04 1.3 (1-1.8) .04
CMV status neg-neg .4 (1-1.5) .2 .6 (.3-1.2) .2 .6 (.4-1) .04
High-risk disease 2.5 (1.2-5) .01 1.2 (.8-1.8) .4 1 (.7-1.2) .6
PBSC vs. other 1.8 (.6-5.7) .3 .9 (.4-1.8) .7 .7 (.4-1.2) .2
Lymphoid vs. myeloid .5 (.3-1) .05 1 (.7-1.4) 1 .9 (.7-1.1) .3
Flu-bu vs. other 1.8 (.9-3.5) .1 .9 (.6-1.3) .5 1 (.8-1.4) .8
Time to HCT >12 mo .4 (1-1.8) .2 1.2 (.6-2.4) .7 1.1 (.6-1.8) .8
Year of HCT (1999-2003)
TCD .9 (.4-2) .8 1.4 (.9-2.3) .13 1.2 (.8-1.8) .3
EBMT score
1-3 1.0 1.0 1.0
4-7 2 (1-4.1) .06 1.4 (.9-2.2) .09 1.3 (.9-1.7) .1
HCT-CI
0 1.0 1.0 1.0
1-2 2 (.6-6.2) .2 1.6 (.9-3) .09 1.4 (.8-2) .17
3 3.9 (1.4-10.9) .01 2.2 (1.3-3.8) .004 1.8 (1.3-2.7) .002
Multivariate analysis
Age > 60 d 2 (1.3-3) .002 1.6 (1.2-2.2) .005
HLA alternative 2.5 (1.3-4.8) .007 2.4 (1.6-3.7) <.001 1.8 (1.3-2.5) .001
Female to male d 1.5 (1.1-2.2) .02 1.3 (1-1.8) .05
High-risk disease 2.6 (1.3-2.5) .01 d d
HCT-CI
0 1.0 1.0 1.0
1-2 1.9 (.7-6) .3 1.6 (.9-3) .09 1.3 (.8-2) .2
3 4.4 (1.5-13) .007 2.3 (1.3-3.8) .003 1.9 (1.3-2.8) .002
EBMT score
1-3 1.0 1.0 1.0
4-7 1.2 (.5-3.1) .7 1.4 (.9-2.1) .1 1.2 (.9-1.7) .2
CMV indicates cytomegalovirus; PBSC, peripheral blood stem cells; Flu-bu, ﬂudarabine and busulfan; TCD, T cell depletion.
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(19%); HCT-CI ¼ 1 to 2, n ¼ 130 (29%); and HCT-CI  3,
n ¼ 225 (51%). According to the EBMT score, 62 (14%), 64
(14%), 130 (29%), 128 (29%), and 61 (14%) patients had a score
of 0 to 2, 3, 4, 5, and 6 to 7, respectively.
Patients with higher HCT-CI showed higher risk of NRM at
100 days (HCT-CI¼ 0, reference [ref]; HCT-CI ¼ 1 to 2, hazard
ratio [HR],1.9 [95% conﬁdence interval {CI}, .7 to 6], P¼ .2; and
HCT-CI 3, HR, 4.4 [95% CI, 1.5 to 13], P¼ .007) and at 4 years
(HCT-CI ¼ 0, ref; HCT-CI ¼ 1 to 2, HR, 1.6 [95% CI, .9 to 3],
P ¼ .09; and HCT-CI  3, HR, 2.3 [95% CI, 1.3 to 3.8], P ¼ .003)
and a lower probability of OS (HCT-CI¼ 0, ref; HCT-CI¼ 1 to 2,
HR, 1.3 [95% CI, .8 to 2], P¼ .2; and HCT-CI 3, HR, 1.9 [95% CI,
1.3 to 2.8], P ¼ .002) in the MVA (Table 2). The c-statistic for
the HCT-CI for NRM was .601 (c-95% CI, .55 to .64).
Patients with higher EBMT scores showed a trend to an
increased risk of 4-year NRM (EBMT score¼ 0 to 3, ref; EBMT
score¼ 4 to 7, HR,1.4 [95% CI, .9 to 2.1], P¼ .1) and similar risk
of 100-day NRM (EBMT score¼ 0 to 3, ref; EBMT score ¼ 4 to
7, HR, 1.2 [95% CI, .5 to 3.1], P ¼ .7) and 4-year OS (EBMT
score ¼ 0 to 3, ref; EBMT score ¼ 4 to 7, HR, 1.2 [95% CI, .9 to
1.7], P ¼ .2) than patients with low EBMT scores. Regarding
individual scores, an increased risk of 100-day NRM (HRs of
1.0 (ref), .8, 1.2, 1.6, and 3.9 for EBMT scores of 0 to 2, 3, 4, 5,
and 6 to 7, respectively [global P ¼ .003]) and 4-year NRM
(HRs of 1.0, .8, 1.1, 1.2, and 2.4 for EBMT scores of 0 to 2, 3, 4, 5,
and 6 to 7, respectively [global P ¼ .007]) were observed in
higher EBMT scores. There was a nonsigniﬁcant trend for
worse OS in patients with higher EBMT scores (HRs 1.0, .8, 1.1,
1.1, and 1.6 for EBMT scores of 0 to 2, 3, 4, 5, and 6 to 7,
respectively [global P ¼ .08]). The c-statistic for the EBMT
score for NRMwas .542 (c-95% CI, .51 to .58), and a trend to a
lower predictive capacity than the HCT-CI was observed(P ¼ .1). More detailed information on the impact of all EBMT
scores on NRM and OS is summarized in Supplementary
Table 1.
Combination Model
After integrating the HCT-CI and the EBMT score as
detailed in Methods, a new combination model was built.
The distribution of patients according to the 6 categories of
the new combination model is summarized in Table 3 and
ranged from 32 patients (7%) in group 1 (HCT-CI ¼ 0 and
EBMT score <4) to 168 patients (38%) in group 6 (HCT-CI  3
and EBMT score 4).
Risks of NRM and OS according to the 6-category model
combining HCT-CI and EBMT score are summarized in Table 3,
Figure 1, and Supplementary Figure 1. In the group of HCT-
CI¼ 0, patients with EBMTscore<4 (group 1) and EBMTscore
4 to 7 (group 2) had similar NRM (20% [95% CI, 10% to 42%]
versus 19% [95% CI, 11% to 33%], P ¼ .9) and OS (54% [95% CI,
44% to 64%] versus 63% [95% CI, 56% to 70%], P ¼ .5). Also, in
the group of HCT-CI ¼ 1 to 2, patients with EBMT score <4
(group 3) and EBMT score 4 to 7 (group 4) had similar NRM
(28% [95% CI, 17% to 48%] versus 28% [95% CI, 20% to 39%],
P ¼ .8) and OS (58% [95% CI, 50% to 66%] versus 53% [95% CI,
48% to 58%], P ¼ .4). Regarding the group of HCT-CI  3, pa-
tients with EBMT score <4 (group 5) had lower NRM (25%
[95% CI, 16% to 39%] versus 40% [95% CI, 33% to 48%], P ¼ .04)
and a trend to higher OS (52% [95% CI, 45% to 59%] versus 36%
[95% CI, 32% to 40%], P ¼ .06) than patients with EBMT score
4 to 7 (group 6). Additionally, patients in group 5 (HCT-
CI  3 and EBMT score <4) had similar NRM (25% [95% CI,
16% to 39%] versus 28% [95% CI, 20% to 37%], P ¼ .5) and OS
(52% [95% CI, 45% to 59%] versus 54% [95% CI, 50% to 58%],
P ¼ .9) than patients in groups 3 and 4 (HCT-CI ¼ 0 to 2).
Table 3
Patient Distribution and Transplant Outcomes According to the New 6-Category Model
N (%) 4-Year NRM 4-Year OS
Events (%) HR (95% CI) Percent Alive (%) HR (95% CI) Percent (95%CI)
Group 1: HCT-CI ¼ 0 and EBMT score <4 32 (7) 6 (19) 1 (ref) 20 19 (59) 1 (ref) 54 (44-64)
Group 2: HCT-CI ¼ 0 and EBMT score 4 55 (12) 10 (18) 1 (.4-2.7) 19 36 (66) .8 (.4-1.6) 63 (56-70)
Group 3: HCT-CI ¼ 1-2 and EBMT score <4 37 (8) 10 (27) 1.4 (.5-3.9) 28 22 (60) .9 (.5-2) 58 (50-66)
Group 4: HCT-CI ¼ 1-2 and EBMT score 4 93 (21) 25 (27) 1.6 (.7-4) 28 51 (55) 1.2 (.7-2.3) 53 (48-58)
Group 5: HCT-CI 3 and EBMT score <4 57 (13) 14 (25) 1.4 (.5-3.6) 25 32 (54) 1.2 (.6-2.3) 52 (45-59)
Group 6: HCT-CI 3 and EBMT score 4 168 (38) 63 (38) 2.5 (1.1-5.8) 40 67 (39) 1.8 (1-3.2) 36 (32-40)
Total 442 (100) 128 (29) d 30 227 (51) d 48 (46-51)
NRM and OS according to the new 6-category model integrating the HCT-CI and EBMT score. P value for transplant outcomes between group 6 and group 5: 4-
year NRM, P ¼ .04; 4-year OS, P ¼ .06. P value for transplant outcomes between group 5 and groups 3 and 4 (together): 4-year NRM, P ¼ .5; 4-year OS, P ¼ .9.
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Nonrelapse mortality
Overall, 56 (13%) and 131 patients (30%) experienced NRM
at 100 days and at 4 years, respectively. Cumulative incidence
of 4-year NRM was 30% (95% CI, 26% to 35%). The most
common causes of NRM were GVHD and infections (51 pa-
tients died from GVHD with infection, 45 from infection
without GVHD, and 27 from GVHD without infection).
Risk factors for NRM in the MVA are summarized in
Table 2. The impacts of HCT-CI and EBMT score and the
combination model have been shown. Other variables asso-
ciated with a higher risk of 100-day NRM were donor type
(non-HLA identical sibling donors: HR, 2.5 [95% CI, 1.3 to 4.8],
P ¼ .007) and high-risk diseases (HR, 2.6 [95% CI, 1.3 to 2.5],
P ¼ .01). Other variables associated with a higher risk of 4-
year NRM were donor type (non-HLA identical siblings: HR,
2.4 [95% CI, 1.6 to 3.7], P < .001), age at HCT (age > 60 years:
HR, 2 [95% CI,1.3 to 3], P¼ .002), and donorerecipient gender
combination (female-to-male: HR, 1.5 [95% CI, 1.1 to 2.2],
P ¼ .02). For the subset of patients with HCT-CI ¼ 0 (groups 1
and 2) and HCT-CI ¼ 1 to 2 (groups 3 and 4), no risk factors
for NRM could be identiﬁed (Supplementary Table 2).
Relapse and OS
Globally, 145 patients (33%) experienced relapse of base-
line disease, for a cumulative incidence of 32% (95% CI, 28% to
37%) at 4 years. A total of 227 patients (51%) remained alive at
median follow-up for a probability of 4-year OS of 48% (95%
CI, 46% to 51%). The impact of HCT-CI and EBMT score and the
combination model on OS has been shown. Other variables
associated with worse OS in the MVAwere donor type (non-
HLA identical siblings: HR, 1.8 [95% CI, 1.3 to 2.5], P ¼ .001),
age at HCT (age > 60 years: HR, 1.6 [95% CI, 1.2 to 2.2],
P ¼ .005), and donorerecipient gender combination (female-
to-male: HR, 1.3 [95% CI, 1 to 1.8], P ¼ .05).
Other transplant outcomes
Neutrophil (>.5  109/L) and platelet (>50  109/L) re-
covery occurred at a median of 15 days (range, 9 to 68) and
19 days (range, 8 to 203), respectively. Globally, 436 and 380
patients were assessable for acute and chronic GVHD,
respectively. Cumulative incidence of grades II to IV acute
GVHD and any grade of chronic GVHD were 26% (95% CI, 22%
to 30%) and 51% (95% CI, 46% to 56%), respectively.
DISCUSSION
This is the ﬁrst published study integrating 2 commonly
used predictive models in the HCT setting (the HCT-CI and
the EBMT score) in a large population of allo-HCT recipients,
showing that the consideration of the EBMT score in patients
with HCT-CI 3 results in a better discrimination of high-riskpatients. This information is especially relevant in patients
undergoing reduced-toxicity allo-HCT because these patients
are more likely to have advanced comorbidities.
The HCT-CI and EBMT score were developed in very large
cohorts of HCT patients and have been studied in other set-
tings, including different diseases, stem cell sources, and
conditioning regimens. Whereas the HCT-CI summarizes 17
comorbid conditions of the patients under 1 score, the EBMT
score is a global prognostic model including several
transplant-related variables. Many studies have conﬁrmed
their predictive capacity for several transplant outcomes [6-
10], although some others have not [19,20]. Furthermore,
each of these models looks at a particular group of risk fac-
tors but neglects some others. For instance, the HCT-CI in-
cludes a high number of carefully selected comorbid
conditions but does not consider other patient- and
transplant-related variables such as age, disease status, and
donor type, which have been associated with an adverse
outcome after the procedure. In addition, the EBMT score
does not consider comorbidities and assigns the same
theoretical risk to a ﬁt patient as it does to a recipient with
renal, hepatic, and pulmonary impairment with similar
transplant-related characteristics.
In clinical practice, variables included in both models are
considered daily when facing decisions on the intensity of
conditioning and even transplant indication for a particular
patient. Moreover, the ﬁnal score of these models is usually
taken into account, although data on how to integrate this
information are lacking. For instance, it is not clear how to
proceed with a patient with high risk of mortality according
to 1 model (ie, HCT-CI ¼ 5) but with low risk according to
another model (ie, EBMT score ¼ 1). A few studies have
separately applied each of these 2 models to the same cohort
of patients [20,21] with disparity of results between them.
Others have evaluated the addition of some variables
included in the EBMT score to the HCT-CI. Hence, Sorror et al.
[22] combined the HCT-CI with disease status, showing that
this combination allowed a better stratiﬁcation of patients at
high risk of NRM after the procedure. Nonetheless, these
models have not been fully integrated before.
Our results show that after combining both models, pa-
tients within low (score ¼ 0) and intermediate (score ¼ 1 to
2) HCT-CI risk groups had similar outcome irrespective of
their EBMT score. Moreover, no individual pretransplant
characteristics were identiﬁed as potential risk factors for
NRM in patients with HCT-CI of 0 to 2, suggesting that if
medically ﬁt, a patient can handle the risk of having an
unrelated donor or an unfavorable gender combination be-
tween donor and recipient. However, in patients with more
and severer comorbidities (HCT-CI  3), having a high EBMT
score was associated with worse outcome after the
Figure 1. NRM mortality according to the HCT-CI, EBMT score, and the combination model. Cumulative incidence estimates (and 95% CI) of NRM according to the
HCT-CI (A), EBMT score (B), and the integration of both models (C).
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EBMT scores had a risk of NRM at 4 years of 40%. Thus, pa-
tients within this group and at high risk of relapse according
to biological characteristics of their diseases (which are not
included in the EBMT score) should be carefully selected for
allo-HCT due to a very low probability of surviving long term.
On the other hand, the risk of NRM for patients with HCT-CI
 3 and low EBMT scores (group 5) was similar to the risk of
patients with HCT-CI score ¼ 1 to 2 (groups 3 and 4), sug-
gesting that patients with advanced comorbidities and low
EBMT scores should be considered similarly to those with
intermediate HCT-CI. This information is especially relevant
in patients receiving allo-HCT with reduced-toxicity condi-
tioning, because up to two thirds [19,22] of these patients
have HCT-CI  3.
We and others have reported that the predictive capacity
in an individual patient of these models is lower than 70%
[2,23]. In our study, the c-statistic for bothmodels was rather
low (<.65), and there was a trend to a better predictive ca-
pacity for the HCT-CI compared with the EBMT score. Thus, it
seems that further efforts are needed in the predictive model
ﬁeld to reach a better characterization of high-risk patients.
To that end, the integration of pretransplant models reported
herein might be a useful but not the sole strategy to improve
their predictive capacity. For instance, it is necessary to up-
date these models to the current HCT practice. Regarding the
EBMT score, several groups have suggested some modiﬁca-
tions to the model, such as the addition of an extra point to
the age category for patients >60 years and the modiﬁcation
of the parameter time from diagnosis to transplant in some
baseline diseases [21,24]. Also, the disease risk category
could be revised by adding biological characteristics of the
diseases, including cytogenetics in AML and histological
subtype in lymphomas. Recently, a new risk model consid-
ering these biological characteristics has been developed and
validated in a large HCT population [4] and could be used as a
guide to redeﬁne the disease risk. Regarding the HCT-CI, a
more detailed redeﬁnition of some comorbidities such as
previous infection could also be considered. Another
important issue is the standardization and simpliﬁcation of
data collection. To that end, some general recommendations,
web-based tools, and training programs have been proposed
and have shown positive results in the improvement of the
interobserver agreement rate [25].
The limited predictive capacity of the EBMT score in our
cohort is a limitation of our study andmight be explained by
the simpliﬁcation of the EBMT scores into 2 groups and the
heterogeneity of baseline diseases. Other limitations might
be derived from the retrospective perspective of the study.
In conclusion, our study demonstrates that the combi-
nation of HCT-CI and the EBMT score is feasible and might
contribute to a better identiﬁcation of high-risk patients,
improving selection of best allo-HCT candidates. Our results
suggest that patients with advanced comorbidities but low
EBMT scores should be considered similarly as patients with
intermediate HCT-CI, whereas patients with high HCT-CI
and EBMT scores have a very high probability of devel-
oping transplant-related complications. However, these
ﬁndings should be conﬁrmed in independent populations of
HCT recipients before their implementation in clinical
practice.
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